APA (7th ed.) Citation

Rosenfeld, P. J., Schwartz, S. D., Blumenkranz, M. S., Miller, J. W., Haller, J. A., Reimann, J. D., . . . Shams, N. (2005). Maximum Tolerated Dose of a Humanized Anti–Vascular Endothelial Growth Factor Antibody Fragment for Treating Neovascular Age-Related Macular Degeneration. Ophthalmology (Rochester, Minn.), 112(6), 1048-1053.e4. https://doi.org/10.1016/j.ophtha.2005.01.043

Chicago Style (17th ed.) Citation

Rosenfeld, Philip J., Steven D. Schwartz, Mark S. Blumenkranz, Joan W. Miller, Julia A. Haller, James D. Reimann, William L. Greene, and Naveed Shams. "Maximum Tolerated Dose of a Humanized Anti–Vascular Endothelial Growth Factor Antibody Fragment for Treating Neovascular Age-Related Macular Degeneration." Ophthalmology (Rochester, Minn.) 112, no. 6 (2005): 1048-1053.e4. https://doi.org/10.1016/j.ophtha.2005.01.043.

MLA (9th ed.) Citation

Rosenfeld, Philip J., et al. "Maximum Tolerated Dose of a Humanized Anti–Vascular Endothelial Growth Factor Antibody Fragment for Treating Neovascular Age-Related Macular Degeneration." Ophthalmology (Rochester, Minn.), vol. 112, no. 6, 2005, pp. 1048-1053.e4, https://doi.org/10.1016/j.ophtha.2005.01.043.